Name: Cancer Drug Safety and Public Health Policy: A Changing Landscape (en Inglés)
Price: 123.49 USD
Availability: InStock
Author: Bennett, Charles ; Lubaczewski, Courtney ; Witherspoon, Bartlett
ISBN: 9783031044045

portada Cancer Drug Safety and Public Health Policy: A Changing Landscape (en Inglés)

Cancer Drug Safety and Public Health Policy: A Changing Landscape (en Inglés)

Formato

Libro Físico

Editorial

Springer

Autor

Bennett, Charles ; Lubaczewski, Courtney ; Witherspoon, Bartlett

Idioma

Inglés

N° páginas

167

Encuadernación

Tapa Blanda

ISBN13

9783031044045

N° edición

Categorías

Oncología
Farmacología

Cancer Drug Safety and Public Health Policy: A Changing Landscape (en Inglés)

Bennett, Charles ; Lubaczewski, Courtney ; Witherspoon, Bartlett (Autor) · Springer · Tapa Blanda

Libro Nuevo Importado

Envío: 25 a 33 días háb.

$ 224.53$ 123.49

-45%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 100 unidades

$ 123.49

Llega entre el 07 Sep y el 21 Sep a Quito, Pichincha. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Cancer Drug Safety and Public Health Policy: A Changing Landscape (en Inglés)"

This book offers a wide-ranging description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. The book opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention - these fines are playing an important role in changing the landscape for pharmaceutical safety.